IFLR1000

Takeda Pharmaceutical $5.2 billion acquisition of Ariad Pharmaceuticals

9/1/2017
Public acquisition
Select tab

$ 5.2 billion

Announced

9/1/2017

Overview:

  • Japanese pharmaceutical company Takeda has acquired US oncology drug maker Ariad Pharmaceuticals in a $5.2 billion deal.
  • The price tag comes to $24 per Ariad share.
  • Hedge fund Ariad investor Sarissa Capital Management is expected to tender its shares if the deal is completed.
  • Evercore Partners served as Takeda's financial adviser.
  • JPMorgan, Lazard and Goldman Sachs acted as financial advisers for Ariad.
  • The transaction is expected to close by the end of this upcoming February.

Kurt Stumpo - Journalist

Jurisdictions:

United States
Japan

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Cleary Gottlieb Steen & Hamilton

Party: Takeda Pharmaceuticals (Acquirer)

Lawyers: Kimberly Spoerri, Paul Shim

Fried Frank Harris Shriver & Jacobson

Party: Goldman Sachs (Financial adviser)

Lawyer: Philip Richter

Paul Weiss Rifkind Wharton & Garrison

Party: Ariad Pharmaceuticals (Target)

Lawyers: Brian Lavin, Jeffrey Marell, John Kennedy, Manuel Frey, Scott Barshay

Simpson Thacher & Bartlett

Party: JPMorgan Chase (Financial adviser)

Lawyer: Caroline Gottschalk

Sullivan & Cromwell

Party: Lazard (Financial adviser)

Lawyer: Keith Pagnani

Related deals